Literature DB >> 23611715

Micro-ribonucleic acids in head and neck cancer: an introduction.

I Gunawardena1, J Fitzgerald, A Morley, D J Hussey, C M Woods, A S Carney.   

Abstract

BACKGROUND AND METHODS: Head and neck cancer is the sixth most common cancer worldwide. Advances in management have not greatly altered overall survival. Over the last decade, there have been significant scientific advances in our knowledge of cell cycle regulation and the complex oncogenic processes. MicroRNAs are small, non-coding RNAs which are integral to the regulation of gene expression and which play a part in carcinogenesis. The literature on the role of microRNA in head and neck cancer is reviewed.
OBJECTIVE: To introduce the role and significance of microRNAs in head and neck cancer.
RESULTS: The possibilities of incorporating microRNAs into clinical practice are discussed, including their potential role in diagnosis, prognosis, prediction of metastatic spread, therapy and tumour surveillance.
CONCLUSION: Discoveries in expression profiling of microRNA in head and neck oncology promise advancements in the diagnosis, prognosis and therapy of these cancers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23611715     DOI: 10.1017/S0022215113000753

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  2 in total

1.  Expression Levels and Clinical Significance of miR-21-5p, miR-let-7a, and miR-34c-5p in Laryngeal Squamous Cell Carcinoma.

Authors:  Massimo Re; Giuseppe Magliulo; Federico M Gioacchini; Arisa Bajraktari; Andrea Bertini; Artan Çeka; Corrado Rubini; Luigi Ferrante; Antonio D Procopio; Fabiola Olivieri
Journal:  Biomed Res Int       Date:  2017-08-31       Impact factor: 3.411

2.  Role of a genetic variation in the microRNA-4421 binding site of ERP29 regarding risk of oropharynx cancer and prognosis.

Authors:  Juliana Carron; Ana Paula Dalla Costa; José Augusto Rinck-Junior; Fernanda Viviane Mariano; Benilton de Sá Carvalho; Carmen Silvia Passos Lima; Gustavo Jacob Lourenço
Journal:  Sci Rep       Date:  2020-10-12       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.